Tokyo - Delayed Quote JPY

Delta-Fly Pharma, Inc. (4598.T)

647.00

+44.00

+(7.30%)

At close: May 30 at 3:30:00 PM GMT+9

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan, February 28, 2025--Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status.

Business Wire 3 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan, December 09, 2024--Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status.

Business Wire 5 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

TOKUSHIMA, Japan, December 04, 2024--We are excited to share our latest development status.

Business Wire 5 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

TOKUSHIMA, Japan, November 26, 2024--We are excited to share our latest development status.

Business Wire 6 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

TOKUSHIMA, Japan, November 05, 2024--We are excited to share our latest development status.

Business Wire 6 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data

TOKUSHIMA, Japan, October 28, 2024--Following to the previous information on September 10th. 2024, we are excited to share our latest development status.

Business Wire 6 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients

TOKUSHIMA, Japan, September 10, 2024--Following to the previous information on April 8th. 2024, we are excited to share our latest development status.

Business Wire 8 months ago

4598.T
+7.30%
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

TOKUSHIMA, Japan, July 03, 2024--We are excited to share our latest development status.

Business Wire 10 months ago

4598.T
+7.30%

Performance Overview

Return	4598.T	Nikkei 225 (^N225)
YTD	+14.11%	-4.84%
1-Year	+34.79%	-0.23%
3-Year	-27.63%	+38.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Delta-Fly Pharma, Inc. (4598.T)

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data

Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients

Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323

Performance Overview